AbbVie confirms deal to buy Allergan for $61.7 billion, a 45% premium
AbbVie Inc.
confirmed Tuesday a deal to buy pharmaceutical company Allergan PLC AGN, -0.95% in a deal with equity value of $63 billion. Allergan's stock soared 30% in premarket trading while AbbVie shares tumbled 9.9%. Under terms of the deal, Allergan shareholders will receive 0.8660 and $120.30 in cash for each Allergan share they own, which based on Monday closing prices values Allergan shares at $188.24 each, a 45.3% premium. Based on 327.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Abbvie is buying Allergan in a $63 billion pharma mega-dealThe biopharmaceuticals giant and drugmaker are combining to create a leader across immunology, neuroscience, eye care and other medical fields.
Read more »
AbbVie Nears Deal to Buy Allergan for More Than $60 BillionAbbVie is nearing a deal to buy Allergan for more than $60 billion, as the two big drug makers bet a combination will deliver new sources of growth they have struggled to find on their own.
Read more »
AbbVie Nears Deal to Buy Allergan for More Than $60 BillionAbbVie is nearing a deal to buy Allergan for more than $60 billion, as the two big drug makers bet a combination will deliver new sources of growth they have struggled to find on their own.
Read more »
Abbvie is buying Allergan in a $63 billion pharma mega-dealThe biopharmaceuticals giant and drugmaker are combining to create a leader across immunology, neuroscience, eye care and other medical fields.
Read more »
Caesars' stock soars after Eldorado buyout deal values casino operator at about $8.6 billionShares of Caesars Entertainment Corp. soared 16% toward an 11-month high in premarket trading Monday, after the casino operator agreed to be bought out by...
Read more »
Circor rejects Crane's buyout deal valued at $1.7 billionCircor International Inc. said Monday it has rejected the unsolicited buyout bid from Crane Co. given that it 'substantially undervalues' the flow...
Read more »